BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating ...

Swiss biotech firm BioVersys has signed a research and licensing agreement with the Japanese pharmaceutical company Shionogi.

Four days ahead of its July 7 PDUFA date, the U.S. FDA granted accelerated approval to Dizal (Jiangsu) Pharmaceutical Co. Ltd.’s sunvozertinib (DZD-9008), branded as Zegfrovy, for treating adults with ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...